FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 323 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use Aiming to Prevent Cancer Cases, ESMO Campaigns Against the Use of ‘Low-Alcohol’ Labelling in Response to the Council Agreement on the EU’s Wine Package MOST POPULAR Program Helps Medically Underserved, Minority Cancer Survivors Be More Active July 3, 2024 Building Your Fort of Support: Tips from a Breast Cancer Social... October 27, 2021 Fewer Women with Ovarian, Breast Cancer Undergo Genetic Testing than Expected April 9, 2019 12 myths about sun safety debunked July 31, 2023 Load more HOT NEWS How People With Cancer Can Make the Most of Televisits FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute... ΣΑΡΚΩΜΑ Nirogacestat Shows Significant Benefit in Patients with Progressing Desmoid Tumours
